CBondlogo-Red.png
C-Bond Systems Partners with THOMS Aviation, THOMS Automotive, and EXEGi Trading Company in Joint Marketing and Distribution Agreements to Expand its Nano Products Portfolio
March 30, 2020 08:31 ET | C-Bond Systems
THOMS Aviation and Automotive Products include Antibacterial and Antiviral Protection for Covid-19 and Other Pathogens THOMS’ Current Customers Include Transavia, KLM Cityhopper and EasyJet HOUSTON,...
Business Capital Delivers $5.5 Million Financing for Wedderspoon
January 14, 2020 07:00 ET | Business Capital
SAN FRANCISCO, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Business Capital structured and delivered a $5.5MM  working capital facility for Wedderspoon, the largest seller of Manuka honey and its portfolio of...
2019 logo_150x35_jpg.jpg
Novan Further Expands its Proprietary Nitric Oxide Platform
October 18, 2019 08:30 ET | Novan, Inc.
A new product candidate, SB207, to target anti-viral opportunitiesPre-IND meeting anticipated in December 2019Development of SB207 to be focused on indications with unmet patient need, such as...
novan logo.jpg
Novan SB206 Phase 3 Molluscum Pivotal Program Update
July 11, 2019 08:15 ET | Novan, Inc.
More than 50 percent of total expected patients now enrolledVirtually all of the clinical sites now active Discipline and execution focus remain of equal importance to recruitment activity ...
CidaraLogo (1).jpg
Cidara Provides Corporate Update and Reports First Quarter 2019 Financial Results
May 09, 2019 16:13 ET | Cidara Therapeutics, Inc.
SAN DIEGO, May 09, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
CidaraLogo (1).jpg
Cidara Therapeutics to Present at the 18th Annual Needham Healthcare Conference
April 03, 2019 16:04 ET | Cidara Therapeutics, Inc.
SAN DIEGO, April 03, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that...
CidaraLogo (1).jpg
Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2018 Financial Results
February 28, 2019 16:24 ET | Cidara Therapeutics, Inc.
SAN DIEGO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
novan logo.jpg
Novan Phase 2 Molluscum Contagiosum Trial Achieves Statistical Significance in Preliminary Top Line Results
November 14, 2018 06:30 ET | Novan, Inc.
Higher rates of complete clearance of all molluscum lesions at Week 12 for the two highest doses, SB206 8% and 12% twice-daily, more than double the rate observed in the vehicle groupClear treatment...
novan logo.jpg
Novan Publication Supports Women’s Health Business Unit Initiative and Nitric Oxide’s Potential Against HPV-Associated Diseases
November 01, 2018 08:05 ET | Novan, Inc.
Data from SB206 Phase 2 clinical trial in external genital warts have been published in the Journal of Drugs in DermatologySB206 was efficacious and well tolerated in the trialAdvancement of the late...
novan logo.jpg
Novan Creates Dedicated Women’s Health Business Unit
October 25, 2018 07:05 ET | Novan, Inc.
Business unit will focus on Novan’s proprietary nitric oxide technology and its application to target high-risk human papillomavirus (HPV) and associated cancers affecting women such as cervical...